The Utility of MRD Testing for Myeloma Patient Treatment and Outcomes

The Utility of MRD Testing for Myeloma Patient Treatment and Outcomes

April 12, 2024 Meeting of the Oncologic Drugs Advisory Committee (ODAC)Подробнее

April 12, 2024 Meeting of the Oncologic Drugs Advisory Committee (ODAC)

ASH23: CARTITUDE-2 Trial on Ciltacabtagene Autoleucel in Multiple Myeloma | Jens Hillengass, MD, PhDПодробнее

ASH23: CARTITUDE-2 Trial on Ciltacabtagene Autoleucel in Multiple Myeloma | Jens Hillengass, MD, PhD

ImmunoPET- an Advanced Companion to MRD TestingПодробнее

ImmunoPET- an Advanced Companion to MRD Testing

What is the latest from the International Myeloma Foundation’s Black Swan Research Initiative?Подробнее

What is the latest from the International Myeloma Foundation’s Black Swan Research Initiative?

MRD: its role and importance for myeloma treatmentПодробнее

MRD: its role and importance for myeloma treatment

MRD2STOP: Can multimodal MRD negativity guide discontinuation of maintenance treatment in myeloma?Подробнее

MRD2STOP: Can multimodal MRD negativity guide discontinuation of maintenance treatment in myeloma?

Webinar | Patient and haematologist perspectives on Minimal Residual Disease testing in myelomaПодробнее

Webinar | Patient and haematologist perspectives on Minimal Residual Disease testing in myeloma

Is CAR T-cell therapy being used to treat newly diagnosed multiple myeloma?Подробнее

Is CAR T-cell therapy being used to treat newly diagnosed multiple myeloma?

First-Line or Frontline Therapy Options In Multiple Myeloma | 2023 IMF Patient and Family SeminarПодробнее

First-Line or Frontline Therapy Options In Multiple Myeloma | 2023 IMF Patient and Family Seminar

Approaching MRD in Multiple MyelomaПодробнее

Approaching MRD in Multiple Myeloma

Multiple Myeloma Update: Frontline TherapyПодробнее

Multiple Myeloma Update: Frontline Therapy

Multiple Myeloma: Minimal Residual DiseaseПодробнее

Multiple Myeloma: Minimal Residual Disease

Measurable Residual Disease (MRD) in AML and ALLПодробнее

Measurable Residual Disease (MRD) in AML and ALL

Individualizing Transplant Decisions Based on Depth of Response in MyelomaПодробнее

Individualizing Transplant Decisions Based on Depth of Response in Myeloma

Can blood testing replace bone marrow testing for multiple myeloma?Подробнее

Can blood testing replace bone marrow testing for multiple myeloma?

Multiple Myeloma Update: Maintenance TherapyПодробнее

Multiple Myeloma Update: Maintenance Therapy

Finding the Cure: Exploring the potential of MRD as a novel endpointПодробнее

Finding the Cure: Exploring the potential of MRD as a novel endpoint

The relevance of MRD assessment in the clinical management of Multiple Myeloma (MM) patientsПодробнее

The relevance of MRD assessment in the clinical management of Multiple Myeloma (MM) patients

Your cheat sheet for smarter Clinical Flow Cytometry testingПодробнее

Your cheat sheet for smarter Clinical Flow Cytometry testing